title: Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
abstract: PURPOSE To determine whether plasma estradiol (E2) levels are related to gene expression in estrogen receptor (ER)-positive breast cancers in postmenopausal women. Materials and METHODS Genome-wide RNA profiles were obtained from pretreatment core-cut tumor biopsies from 104 postmenopausal patients with primary ER-positive breast cancer treated with neoadjuvant anastrozole. Pretreatment plasma E2 levels were determined by highly sensitive radioimmunoassay. Genes were identified for which expression was correlated with pretreatment plasma E2 levels. Validation was performed in an independent set of 73 ER-positive breast cancers. Results The expression of many known estrogen-responsive genes and gene sets was highly significantly associated with plasma E2 levels (eg, TFF1/pS2, GREB1, PDZK1 and PGR; P < .005). Plasma E2 explained 27% of the average expression of these four average estrogen-responsive genes (ie, AvERG; r = 0.51; P < .0001), and a standardized mean of plasma E2 levels and ER transcript levels explained 37% (r, 0.61). These observations were validated in an independent set of 73 ER-positive tumors. Exploratory analysis suggested that addition of the nuclear coregulators in a multivariable analysis with ER and E2 levels might additionally improve the relationship with the AvERG. Plasma E2 and the standardized mean of E2 and ER were both significantly correlated with 2-week Ki67, a surrogate marker of clinical outcome (r = -0.179; P = .05; and r = -0.389; P = .0005, respectively). CONCLUSION Plasma E2 levels are significantly associated with gene expression of ER-positive breast cancers and should be considered in future genomic studies of ER-positive breast cancer. The AvERG is a new experimental tool for the study of putative estrogenic stimuli of breast cancer.
authors.affiliation: Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Rd, London, SW3 6JJ, United Kingdom. anita.dunbier@icr.ac.uk
authors.forename: Anita K
authors.initials: AK
authors.lastname: Dunbier
authors.forename: Helen
authors.initials: H
authors.lastname: Anderson
authors.forename: Zara
authors.initials: Z
authors.lastname: Ghazoui
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Folkerd
authors.forename: Roger
authors.initials: R
authors.lastname: A'hern
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Crowder
authors.forename: Jeremy
authors.initials: J
authors.lastname: Hoog
authors.forename: Ian E
authors.initials: IE
authors.lastname: Smith
authors.forename: Peter
authors.initials: P
authors.lastname: Osin
authors.forename: Ashutosh
authors.initials: A
authors.lastname: Nerurkar
authors.forename: Joel S
authors.initials: JS
authors.lastname: Parker
authors.forename: Charles M
authors.initials: CM
authors.lastname: Perou
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Ellis
authors.forename: Mitch
authors.initials: M
authors.lastname: Dowsett
mesh_terms: D000368:Aged; D000077384:Anastrozole; D001943:Breast Neoplasms / Q000097:blood / Q000737:chemistry / Q000378:metabolism*; D004958:Estradiol / Q000097:blood*; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000032:analysis*; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D004967:Estrogens; D019394:Ki-67 Antigen; D009570:Nitriles; D011960:Receptors, Estrogen; D014230:Triazoles; D000077384:Anastrozole; D004958:Estradiol